These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 12531839)
1. FDA insists that oestrogen products for menopause carry a warning. Gottlieb S BMJ; 2003 Jan; 326(7381):126. PubMed ID: 12531839 [No Abstract] [Full Text] [Related]
2. FDA to require dementia warning on hormones. Health News; 2004 Apr; 10(4):5. PubMed ID: 15088578 [No Abstract] [Full Text] [Related]
3. No fountain of youth: FDA and NIH review off-label use of hormones. Hanna KE Hastings Cent Rep; 2003; 33(4):8-9. PubMed ID: 12971054 [No Abstract] [Full Text] [Related]
4. FDA acts on estrogen, progestin labeling. FDA Consum; 1977 Nov; 11(9):3. PubMed ID: 10305006 [No Abstract] [Full Text] [Related]
5. Progestational drug products for human use; requirements for labeling directed to the patient. Food and Drug Administration, HHS. Final rule. Fed Regist; 1999 Nov; 64(220):62110-2. PubMed ID: 11010691 [TBL] [Abstract][Full Text] [Related]
6. Guidelines for hormone treatment of women in the menopausal transition and beyond. Naftolin F; Schneider HP; Sturdee DW; Maturitas; 2005 May; 51(1):15-20. PubMed ID: 15883104 [No Abstract] [Full Text] [Related]
7. [Possibilities and limitations of hormone therapy between puberty and the menopause]. Kopera H Munch Med Wochenschr; 1972 Apr; 114(16):754-60. PubMed ID: 5067882 [No Abstract] [Full Text] [Related]
10. [Hormonal substitution after menopause--advantages and risks]. Bengtsson C Lakartidningen; 1990 Dec; 87(50):4331-3. PubMed ID: 2280638 [No Abstract] [Full Text] [Related]
11. Informing patients about estrogens. Schmidt AM FDA Consum; 1976 Nov; 10(9):8-9. PubMed ID: 829330 [TBL] [Abstract][Full Text] [Related]
12. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Stefanick ML Am J Med; 2005 Dec; 118 Suppl 12B():64-73. PubMed ID: 16414329 [TBL] [Abstract][Full Text] [Related]
14. Estrogen PPIs. An FDA survey. Morris LA; Myers A; Gibbs P; Lao C Am Pharm; 1980 Jun; NS20(6):22-6. PubMed ID: 7395715 [No Abstract] [Full Text] [Related]
15. United States regulatory considerations for intrauterine progestins for hormone replacement therapy. Rarick L Contraception; 2007 Jun; 75(6 Suppl):S140-3. PubMed ID: 17531606 [TBL] [Abstract][Full Text] [Related]
16. Did FDA jump the gun? Archambault GF Hosp Formul; 1977 Oct; 12(10):722. PubMed ID: 10305387 [No Abstract] [Full Text] [Related]
17. [Menopause: an efficacious therapeutic approach necessitates a global philosophy. Interview by Robert Henry]. Maheux R Union Med Can; 1989; 118(1):6-11. PubMed ID: 2711534 [No Abstract] [Full Text] [Related]
18. Safety of oral contraceptives related to steroid content: a critical review. Sturtevant FM Int J Fertil; 1989; 34(5):323-32. PubMed ID: 2571592 [TBL] [Abstract][Full Text] [Related]
19. Use of menopausal hormones in the United States, 1992 through June, 2003. Wysowski DK; Governale LA Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):171-6. PubMed ID: 15386701 [TBL] [Abstract][Full Text] [Related]